


compound is the second-listed compound of Claims 5 and 31 (which should be renumbered as Claim 30). As the "neurotransmitter-inducing or precursor agent" element of the claims, applicant elects L-phenylalanine. This is the first listed compound of Claim 20 (which should be renumbered as Claim 19) and Claim 29 (which should be renumbered as Claim 28). Applicant makes this election without traverse with the understanding that additional species will be examined upon a finding that the elected species is allowable. Claims 1, 2, 3, 5, 20, 21, 22, 23, 24, 26, 27, 28, 29, and 31 read on the elected species. Note that Claims 20, 21, 22, 23, 24, 26, 27, 28, 29, and 31 should be renumbered as Claims 19, 20, 21, 22, 23, 25, 26, 27, 28, and 30, respectively.

If a telephone interview would be of assistance in advancing the prosecution of the subject application, applicant's undersigned attorney kindly invites the Examiner to telephone at the number provided below.

No fee is believed necessary in connection with filing this Communication. However, if any fee is determined necessary in connection with filing this Communication, the undersigned hereby authorizes charging such fee to Deposit Account No. 16-1445.

Date: Sept. 30, 2004

Respectfully submitted,


Kristina L. Konstas
Attorney for Applicant(s)
Reg. No. 37,864

Pfizer, Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-6380